John Overdeck’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.09M | Buy |
296,293
+128,980
| +77% | +$955K | ﹤0.01% | 2598 |
|
|
2026
Q1 | $1.03M | Buy |
167,313
+76,035
| +83% | +$542K | ﹤0.01% | 3248 |
|
|
2025
Q4 | $658K | Buy |
+91,278
| New | +$738K | ﹤0.01% | 3166 |
|
|
2025
Q2 | – | Sell |
-11,015
| Closed | -$145K | – | 3486 |
|
|
2025
Q1 | $145K | Sell |
11,015
-797
| -7% | -$14.2K | ﹤0.01% | 2907 |
|
|
2024
Q4 | $212K | Sell |
11,812
-1,099
| -9% | -$22.3K | ﹤0.01% | 2862 |
|
|
2024
Q3 | $208K | Buy |
+12,911
| New | +$202K | ﹤0.01% | 2793 |
|
|
2023
Q2 | – | Sell |
-6,711
| Closed | -$280K | – | 3225 |
|
|
2023
Q1 | $280K | Sell |
6,711
-3,873
| -37% | -$182K | ﹤0.01% | 2448 |
|
|
2022
Q4 | $359K | Sell |
10,584
-17,184
| -62% | -$731K | ﹤0.01% | 2171 |
|
|
2022
Q3 | $1.37M | Buy |
27,768
+23,504
| +551% | +$1.29M | ﹤0.01% | 1330 |
|
|
2022
Q2 | $168K | Sell |
4,264
-33,363
| -89% | -$989K | ﹤0.01% | 2196 |
|
|
2022
Q1 | $1.39M | Sell |
37,627
-10,916
| -22% | -$683K | ﹤0.01% | 1527 |
|
|
2021
Q4 | $4.75M | Buy |
48,543
+6,869
| +16% | +$739K | 0.01% | 1224 |
|
|
2021
Q3 | $5.2M | Sell |
41,674
-13,533
| -25% | -$1.63M | 0.01% | 1193 |
|
|
2021
Q2 | $6.92M | Sell |
55,207
-319
| -0.6% | -$38K | 0.02% | 1001 |
|
|
2021
Q1 | $7.54M | Sell |
55,526
-1,706
| -3% | -$212K | 0.02% | 838 |
|
|
2020
Q4 | $5.2M | Buy |
57,232
+31,080
| +119% | +$2.7M | 0.01% | 910 |
|
|
2020
Q3 | $1.95M | Buy |
26,152
+2,393
| +10% | +$183K | 0.01% | 1306 |
|
|
2020
Q2 | $2.02M | Buy |
23,759
+17,665
| +290% | +$1.6M | 0.01% | 1092 |
|
|
2020
Q1 | $441K | Buy |
6,094
+4,545
| +293% | +$439K | ﹤0.01% | 2030 |
|
|
2019
Q4 | $111K | Buy |
1,549
+1,162
| +300% | +$56K | ﹤0.01% | 3516 |
|
|
2019
Q3 | $20K | Buy |
+387
| New | +$20.6K | ﹤0.01% | 3384 |
|
|
2019
Q2 | – | Sell |
-6,171
| Closed | -$439K | – | 3614 |
|
|
2019
Q1 | $439K | Sell |
6,171
-512
| -8% | -$32.5K | ﹤0.01% | 2344 |
|
|
2018
Q4 | $533K | Buy |
6,683
+3,124
| +88% | +$713K | ﹤0.01% | 2060 |
|
|
2018
Q3 | $1.66M | Buy |
3,559
+669
| +23% | +$269K | ﹤0.01% | 1610 |
|
|
2018
Q2 | $1.15M | Buy |
2,890
+849
| +42% | +$301K | ﹤0.01% | 2048 |
|
|
2018
Q1 | $624K | Buy |
2,041
+45
| +2% | +$12.8K | ﹤0.01% | 2341 |
|
|
2017
Q4 | $587K | Buy |
1,996
+259
| +15% | +$113K | ﹤0.01% | 2322 |
|
|
2017
Q3 | $951K | Buy |
+1,737
| New | +$924K | ﹤0.01% | 1755 |
|
Other funds holding RNAC
6CM
John Overdeck's RNAC Position: Q2 2026 in Review
John Overdeck increased its Cartesian Therapeutics (RNAC) stake by 77% in Q2 2026, buying an estimated $955K and bringing the position to 296,293 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2598.
John Overdeck first reported a position in RNAC in Q3 2017 and has held it in 28 quarters since. The position peaked at $7.54M in Q1 2021. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- John Overdeck held 296,293 shares of Cartesian Therapeutics worth $3.09M as of Q2 2026.
- John Overdeck bought 128,980 Cartesian Therapeutics shares in Q2 2026, an estimated $955K.
- Cartesian Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2598 holding.
- John Overdeck first reported a position in Cartesian Therapeutics in Q3 2017 and has held it in 28 quarters since.
- John Overdeck's Cartesian Therapeutics position peaked at $7.54M in Q1 2021.
- 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.